CAR-T cell capable of secreting PD-1 single-domain antibody to target CD19 as well as preparation method and application of CAR-T cell

By using PD-1 single domain antibody secretion antibody to target CD19 in CD19 CAR-T cells, combined with immune checkpoint blocking therapy, the stability and immunogenicity of single-chain antibody fragment domains were solved , which improves the targeted recognition and killing activity of CAR-T cells and achieves effective treatment of CD19-positive tumors.

CN118909947APending Publication Date: 2024-11-08GUANGXI MEDICAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310503179.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the existing CD19 CAR-T cell therapy, the antigen recognition domain based on single-chain antibody fragments (scFv) has problems with folding instability, stickiness, agglomeration and high immunogenicity, resulting in poor treatment effect and drug resistance. Limits its clinical application.

Method used

CAR-T cells targeting CD19 using PD-1 single domain antibody, and T cells modified by chimeric antigen receptor CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP were constructed using lentiviral infection technology. , combined with immune checkpoint blocking therapy, improve the targeted recognition and killing activity of T cells.

Benefits of technology

It enhances the specific targeting and killing activity of CAR-T cells on tumors, prolongs the survival time of cells in vivo, and reduces T cell depletion, providing a new strategy to improve the therapeutic effect of CD19 CAR-T cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909947A_ABST
    Figure CN118909947A_ABST
Patent Text Reader

Abstract

The invention relates to a CAR-T cell capable of secreting a PD-1 single domain antibody targeting CD19 as well as a preparation method and application of the CAR-T cell. The CAR-T cell is a T cell modified by a chimeric antigen receptor CD19Nb-HIStag-CD8-CD137-CD3zeta-PD-1Nb-GFP, the nucleotide sequence of the chimeric antigen receptor is shown as SEQ ID NO.1, and the chimeric antigen receptor has a nucleotide sequence shown as SEQ ID NO.2. The CAR-T cell can be used for secreting a PD-1 single domain antibody targeting CD19. The preparation method of the CAR-T cell comprises the following steps: constructing a recombinant lentiviral vector, packaging a lentivirus, infecting a T cell with the lentivirus, carrying out in-vitro induction, carrying out multiplication culture and obtaining the engineered CAR-T cell capable of secreting a PD-1 single domain antibody to target CD19, and the CD19-PD-1 / Nb CAR-T cell has a relatively good killing effect on CD19 positive tumor cells and can be used for preparing the CAR-T cell capable of secreting the PD-1 single domain antibody to target CD19. The killing effect of the CD19-PD-1 / Nb CAR-T cells on tumor cells is related to the expression quantity of tumor-related cells CD19, and a new strategy is provided for adoptive immunotherapy of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of tumor biological products, and relates to a CAR-T cell (CD19-PD-1 / Nb CAR-T cell) that secretes a PD-1 single domain antibody targeting CD19 in adoptive immunotherapy, and a preparation method and application thereof. Background Art

[0002] Malignant tumors seriously threaten human health and have become the main cause of death. Acute Lymphoblastic Leukemia (ALL) is a common malignant tumor of the blood system, most of which originate from B cells. For a long time, the treatment of malignant tumors generally includes surgical treatment, but this traditional treatment model still has certain limitations, and the toxic side effects after treatment will seriously affect the patient's living standards. Although hematopoietic stem cell transplantation (HSCT) technology has made great progress, current studies have shown that the three-year progression-free survival rate of B-ALL patients who have completed HSCT treatment is about 50%, but the transplantation process is generally expensive, donor scarcity, low efficiency of hematopoietic system reconstruction, and human leukocyte antigen (HLA) matching caused by graft rejection, Graft Versus Host Disease (GVHD) and other complications seriously affect clinical application. Therefore, there is an urgent need to study a new method to improve the treatment of relapsed or refractory ALL.

[0003] With the continuous progress of modern oncology and other disciplines, immunotherapy has brought hope for the treatment of hematological malignancies. Among them, autologous or allogeneic T cells are genetically modified to express chimeric antigen receptors (CAR) and then specifically target tumor cells, which has gradually become a new treatment method that is expected to be used for a wide range of cancers.

[0004] As a new form of treatment, the development of chimeric antigen receptor T cell (CAR-T) technology is obvious to all. CAR consists of an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain. The extracellular antigen recognition domain consists of monoclonal antibodies (mAb) or single chain antibody fragments (scFv) that recognize tumor-associated antigens (TAA), which are connected to the transmembrane region by a hinge. T cells activated by antigens can directly recognize the major histocompatibility complex (MHC)-tumor antigen peptide complex on the cell surface, and then produce granzymes, perforins, and release inflammatory factors such as interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α), and then play a role in killing and clearing tumor cells. According to the different intracellular signal regions, four generations of CAR have been produced. The first generation of CAR contains only one intracellular signal activation receptor, mostly CD3ζ or FcRγ. The full activation of T cells requires co-stimulatory signals, secretion of cytokines, and differentiation and proliferation. Due to the lack of support for co-stimulatory-second signals, the first generation of CAR lost its function soon after activation due to signal limitation, and the effect was not good in clinical trials. There are data showing that its CAR targeting TAA can persist in a small amount in the human body, but its expansion ability and anti-tumor efficacy are low. The second generation of CAR introduced a co-stimulatory molecule, such as CD28, 4-1BB, OX40 or ICOS, on the basis of the first generation, so that T cells can proliferate in the absence of exogenous co-stimulatory molecules. The third generation of CAR adds another co-stimulatory molecule on the basis of the second generation, including two tandem co-stimulatory domains CD28, 4-1BB or OX40 and a CD3ζ, so that T cells can secrete more cytokines, prolong the survival time of T cells in the body, and enhance their anti-tumor efficacy. So far, the latest fourth-generation CAR, also known as TRUCK (T-cells Redirected for Universal Cytokine Killing), has added a transgenic cytokine signal amplification system that can introduce pro-inflammatory cytokines (such as IL-12) while activating T cells, thereby recruiting and activating more immune cells to attack tumor cells, thereby enhancing the anti-tumor effect of CAR-T in the immunosuppressive tumor microenvironment.

[0005] So far, clinical research on CAR-T tumor treatment has mainly focused on blood system malignancies targeting CD19, especially in the treatment of ALL, which has achieved gratifying results. In August 2017, the U.S. FDA approved Novartis' CTL019 (Kymriah, Novartis Pharmaceuticals Corp.) to become the world's first CAR-T therapy to be officially launched for the treatment of patients under 25 years old with refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) or secondary or higher relapses. This is the world's first CAR-T product approved for clinical treatment, and it has also opened up a new model of "gene-modified immune cell therapy" for cancer treatment. In 2018, Maude et al. used Kymriah to treat 75 patients with relapsed or refractory B-ALL, with a total remission rate of 81% within three months, and all patients who responded to the treatment were minimal residual disease (MRD) negative. Kymriah can be observed to persist in the blood within 20 months after treatment, providing durable remission for patients with relapsed or refractory B-ALL, showing good anti-tumor effects.

[0006] Despite this, CD19 CAR-T technology still has many problems that need to be solved. The extracellular antigen recognition domain currently used to construct CAR is mostly scFv fragments that recognize TAA. Although scFv is an ideal guiding antibody, scFv cannot always be effectively folded, and it is easy to stick and aggregate. In addition, scFv fragments are highly immunogenic and may cause immune rejection. In addition, the antigenic epitopes of scFv are limited, which is also the reason why some clinical patients are ineffective or develop drug resistance after receiving CD19 CAR T treatment. The above problems limit the clinical application of CD19 CAR-T technology, so there is an urgent need to study some new strategies to improve the anti-tumor effect of CD19 CAR-T cells.

[0007] Nanobodies (VHH or Nanobodies, Nbs) are unconventional antibodies that naturally lack light chains and were discovered by Belgian scientists Hamers et al. in 1993 from camel serum. They are composed of heavy chain dimers and have a wide range of antigen binding repertoires. The antigen-binding fragment of VHH has only the variable region of the heavy chain antibody, and its structure is stable. It is the smallest unit known to bind to the target antigen, and its affinity is comparable to that of traditional scFv. The immunogenicity of VHH is usually smaller than that of scFv, and its size is small, and it has different epitopes from scFv. Unlike scFv, VHH does not require the additional folding and assembly steps that come with V region pairing. Therefore, due to its advantageous unique structure and functional properties, VHH can be used as a substitute for scFv and become a suitable antigen recognition domain in CAR-T cells. CARs based on single domain antibodies have been produced and show similar functions to scFv-based CARs, demonstrating the flexibility of VHH-based CAR-T cells and their potential for treating tumors.

[0008] Immune checkpoints are a class of immune regulatory molecules. During the occurrence and development of tumors, the activation of immune checkpoints is also one of the main causes of immune tolerance. In recent years, scholars have gradually realized that tumors overexpress immune checkpoint molecules by activating negative regulatory pathways related to immune homeostasis, thereby escaping the body's immune surveillance and effectively suppressing immune responses. Therefore, immune checkpoint blockade therapy has been developed. Immune checkpoint blockade therapy uses antibodies to destroy the interaction between T cell inhibitory receptors and reactivate T cell function, thereby achieving the purpose of anti-tumor. This new immunotherapy has achieved good clinical results in the clinical treatment of a series of patients with solid tumors and hematological malignancies.

[0009] Programmed cell death protein-1 (PD-1, CD279) belongs to the immunoglobulin superfamily and is an important immune negative co-stimulatory receptor. PD-1 is mainly expressed on the surface of activated T cells. It activates the B7-CD28 family-related pathway by binding to its ligand to maintain the balance between T cell activation signals and inhibitory signals, regulate T cell activation, and maintain self-tolerance. Programmed cell death-ligand 1 (PD-L1) is often highly expressed on the surface of malignant tumors. PD-1 can inhibit the activity of T cells and promote their apoptosis by binding to PD-L1, thereby negatively regulating the body's immune function. The PD-1 / PD-L1 pathway has been proven to be widely involved in tumor immunity and other body immunity. Brudno et al. found in their clinical trials that the expression level of PD-1 on CAR-T cells in B-ALL patients was significantly increased after receiving CD19 CAR-T cell therapy, and the administration of PD-1 antagonists can increase the proliferation level of CD19 CAR-T cells. Currently, the FDA has approved the PD-1 inhibitors Pembrolizumab and Nivolumab and the PD-L1 inhibitor Atezolizumab for marketing, and established this immunotherapy as a viable treatment option for patients with advanced cancer, opening the way for the development of a new generation of immunomodulators.

[0010] Based on the highly specific CD19 single-domain antibody screened in our laboratory in the early stage, CAR-T cells are combined with immune checkpoint blockade therapy, and CAR-T cells (CD19-PD-1 / Nb CAR-T) based on secreted PD-1 single-domain antibody targeting CD19 are constructed through lentiviral infection technology for the treatment of hematological malignancies. Compared with the traditional CAR-T cell system, when CD19-PD-1 / Nb CAR-T cells are delivered to tumors, PD-1 blocking single-domain antibodies will be delivered to the disease site, thereby reducing the inhibitory effects associated with immune checkpoints and improving T cell killing activity. This research program provides new basis and strategy for immunotherapy of hematological malignancies. Summary of the invention

[0011] The purpose of the present invention is to provide an engineered CAR-T cell that secretes a PD-1 single domain antibody targeting CD19. Another purpose is to provide a method for preparing the CAR-T cell and to provide the use of the CAR-T cell in preparing a preparation for treating a tumor.

[0012] To achieve the above object, the present invention adopts the following technical solutions:

[0013] A CAR-T cell engineered to secrete a PD-1 single domain antibody targeting CD19, wherein the CAR-T cell is a T cell modified with a chimeric antigen receptor CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.

[0014] The CAR-T cells secreting PD-1 single domain antibody targeting CD19, wherein the nucleotide sequence of the chimeric antigen receptor CD19Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP is shown in SEQ ID NO.1 in the sequence table.

[0015] A method for preparing the CAR-T cells, the method comprising the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of CD19 / Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb-IRES-GFP by PCR, recombining the lentiviral vector after enzyme digestion with the CAR target sequence obtained by PCR, transforming the recombinant lentiviral vector into Escherichia coli, and screening positive clones, sequencing the positive clones to verify whether the lentiviral vector containing the CD19-PD-1 / NbCAR sequence is successfully constructed, extracting plasmids from the recombinant positive clone strains that have been successfully sequenced, transfecting them into cells to be transfected, and then identifying the expression of the CD19-PD-1 / Nb CAR sequence in the cells by RT-PCR, verifying that the recombinant lentiviral vector can be expressed normally and then packaging the lentivirus, preparing T cells, and constructing the CAR-T cells by lentiviral infection technology.

[0016] A method for preparing the CAR-T cells as described above, the method comprising the following steps:

[0017] (1) Construction of a recombinant lentiviral vector containing the CAR target sequence: The CAR target sequence fragment of CD19 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-GFP was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV400 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the primers on the target gene were used to perform PCR identification on the colonies selected by ampicillin antibiotics. The successfully identified bacterial liquid was sequenced, and the plasmid was extracted using the Plasmid Mini Kit after sequencing to obtain the plasmid containing the CAR target sequence;

[0018] (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two auxiliary plasmids Helper1.0 and Helper2.0. After 48 hours, the green fluorescent protein (GFP) expression of the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of green fluorescent protein-positive cells was counted. The virus titer was calculated according to the formula: virus concentration = number of fluorescent cells / volume of virus stock solution in the well;

[0019] (3) T cell preparation: Isolate mononuclear cells from peripheral blood and culture them to obtain T cells;

[0020] (4) Preparation of CD19-PD-1 / Nb CAR-T cells: T cells were cultured for 24 hours using a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody, and human IL-2 cytokine. The next day, the lentivirus solution was added to the stimulated T cells at an MOI of 20 and cultured in a 37°C CO2 incubator for 48 hours. The CAR-T cells were placed under a conventional microscope to observe the GFP expression of the CAR-T cells.

[0021] In step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.

[0022] As in the preparation method described above, the CAR-T cells are prepared using lentiviral infection technology.

[0023] A use of the CAR-T cells that secrete PD-1 single domain antibodies targeting CD19 in the preparation of preparations for treating tumors.

[0024] As in the above application, preferably, the tumor is a CD19 positive tumor.

[0025] A pharmaceutical composition comprising the CAR-T cells that secrete PD-1 single domain antibodies targeting CD19 and a pharmaceutically acceptable carrier.

[0026] A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is CD19Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.

[0027] A chimeric antigen receptor, wherein the chimeric antigen receptor is CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP.

[0028] The researchers of the present invention found that in the immunotherapy of CD19-positive tumors, the advantage of CAR-T cells that secrete PD-1 single-domain antibodies targeting CD19 is specific targeting, that is, enhancing the targeted recognition of tumor antigens by immune cells. In addition, it also enhances the tumor killing activity dependent on the chimeric antigen receptor and the infiltration at the tumor site after infusion, reducing T cell exhaustion. These characteristics possessed by CD19-PD-1 / Nb CAR-T originate from the functional structure of the chimeric antigen receptor, which mainly includes the antigen recognition region and the intracellular activation region. The intracellular activation region can prolong the survival time of cells in vivo. In addition, the present invention uses lentiviral infection to prepare CAR-T cells, and provides a method for efficiently preparing CD19-PD-1 / Nb CAR-T. The CAR-T prepared by this method can stably express the chimeric antigen receptor and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the gel electrophoresis diagram of the CD19-PD-1 / Nb CAR gene sequence synthesized by PCR in Example 2 of the present invention, M: Marker; 1: target gene PCR product.

[0030] Figure 2 Schematic diagram of the recombinant lentiviral vector in Example 3 of the present invention.

[0031] Figure 3 This is a PCR identification diagram of the DH5α positive clone colony in Example 3 of the present invention.

[0032] Figure 4 The packaging and titer detection of the recombinant lentiviral vector in Example 4 of the present invention are shown.

[0033] Figure 5 It shows that the T cells in Example 5 of the present invention express GFP fluorescence after lentiviral transfection.

[0034] Figure 6 The expression of CAR after lentiviral transfection of T cells in Example 5 of the present invention is shown.

[0035] Figure 7 The results show that the T cells in Example 5 of the present invention secrete PD-1 single domain antibodies after lentiviral transfection.

[0036] Figure 8 The expression of CD19 on the surface of three different target cells in Example 6 of the present invention is shown.

[0037] Fig. 9It shows that the CD19-PD-1 / Nb CAR-T in Example 6 of the present invention specifically kills CD19-positive tumor cells, wherein Utd: untransfected T cells, Mock: empty T cells, PD-1 / Nb CAR T: PD-1 single domain antibody CAR T cells, Irrelevant-PD-1 / Nb CAR: CAR T cells that secrete PD-1 targeting an unrelated single domain antibody, CD19 / Nb CAR: CAR T cells that target CD19 with a single domain antibody, CD19 / Nb CAR+PD-1Nb: CAR T cells that target CD19 with a single domain antibody and PD-1 single domain antibody, CD19-PD-1 / Nb CAR: CAR T cells that secrete PD-1 targeting a single domain antibody of CD19. DETAILED DESCRIPTION

[0038] The present invention is further described in detail below in conjunction with specific embodiments. The examples given are only for illustrating the present invention, but not for limiting the scope of the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0039] Example 1 Preparation and activation of T cells

[0040] (1) Density gradient centrifugation to separate peripheral blood T lymphocytes

[0041] Fresh peripheral blood was collected from healthy volunteers using a blood collection tube with anticoagulant, and an equal volume of peripheral blood was mixed with PBS at 37°C. Peripheral blood T lymphocytes were separated by density gradient centrifugation. 4 ml of 37°C sterile lymphocyte separation solution was drawn into a 15 ml centrifuge tube, and 8 ml of diluted peripheral blood was slowly added to the separation liquid surface along the wall of the centrifuge tube. Centrifuge at 2000 rpm for 20 minutes. After the centrifugation, the tube was divided into four layers. The cloudy white film layer cells (PBMC) were carefully drawn along the edge of the centrifuge tube with a Pasteur tube, and the cell suspension was collected into a sterile 50 ml centrifuge tube. Four times the volume of PBS was added and the cells were washed twice. The collected PBMC cells were resuspended with complete cell culture medium RIPM 1640, transferred to a cell culture dish, and cultured in a 37°C cell culture incubator for 2 hours. The suspended cells in the cell culture dish were drawn into another culture dish for culture. The suspended cells were T lymphocytes. T lymphocytes were cultured with complete RIPM 1640 medium containing 100 U / ml rhIL-2.

[0042] (2) T cell culture

[0043] T cells were cultured for 24 hours using a dedicated T cell culture medium containing human CD3, human CD28 monoclonal antibodies, and human IL-2 cytokine.

[0044] Example 2 PCR synthesis of CAR target gene sequence

[0045] The target gene sequence was synthesized and amplified by PCR, and the primers were shown in Table 1 to obtain the CAR fragment of CD19 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-GFP, and finally the band of the target fragment was obtained, as shown in Figure 1 shown.

[0046] 1. Primers

[0047]

[0048] 2. PCR amplification of target gene fragments

[0049] Prepare the following reaction system, add the reagents in the table below in sequence, gently blow to mix the system, centrifuge for a short time, and place the reaction system in a PCR instrument for reaction. The reaction system is as follows:

[0050]

[0051]

[0052] The reaction conditions are as follows:

[0053]

[0054] Example 3 Construction of recombinant lentiviral vector

[0055] The GV400 vector was digested by double enzyme digestion. After digestion, agarose gel electrophoresis showed that the molecular weight of the lentiviral vector plasmid after digestion was about 8Kd, and the band was clear. The lentiviral vector after digestion was recombined with the CAR target sequence obtained by PCR in Example 2 to obtain a recombinant lentiviral vector, such as Figure 2 The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the target gene were used to perform PCR identification on the colonies screened with ampicillin antibiotics. The PCR product electrophoresis was as shown in Figure 3 As shown, 1 is a blank control (ddH2O), 2 is a negative control (empty vector without the target gene inserted), 3 is a positive control (DNA containing the GAPDH gene), 4 is a 5000bp Marker, and 5-12 are transformants 1 to 8 (i.e., 8 randomly selected monoclonal colonies). It can be seen that the lentiviral recombinant vector plasmid containing the target CAR sequence was successfully constructed. The positive clone bacteria were sequenced and compared to be completely consistent with the target sequence.

[0056] Example 4 Lentivirus packaging

[0057] The recombinant positive clones that were successfully sequenced were extracted with the Plasmid Mini Kit and transfected into 293T cells. The recombinant lentiviral vector containing the CAR sequence was co-transfected into 293T cells using a three-plasmid system through two auxiliary vector plasmids (Helper1.0 and Helper 2.0). After 48 hours, the cells were observed under a fluorescence microscope and obvious green fluorescence (GFP) was observed. The supernatant of 293T cells was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of GFP-positive cells was counted. The virus titer was calculated according to the formula: virus concentration = number of fluorescent cells / volume of the virus stock solution in the well, as shown in Figure 2. Figure 4 shown.

[0058] Example 5 Construction of CAR-T cells that secrete PD-1 single domain antibody targeting CD19 (CD19-PD-1 / Nb CAR-T cells)

[0059] (1) Lentiviral infection of T lymphocytes

[0060] T cells were plated into 24-well plates and the cell density in each well was adjusted to 1×10 7 The cells were cultured in a special medium containing 10% FBS, human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine for 24 hours, and the lentivirus was added to the stimulated T cells at an MOI of 20. After 48 hours, the expression of GFP was observed under a fluorescence microscope. Figure 5 As shown, these included CD19-PD-1 / Nb CAR-T cells transfected with lentivirus, CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells (Utd as a negative control).

[0061] (2) Flow cytometry detection of the expression of CAR targeting CD19 in T cells secreting PD-1 single domain antibody

[0062] Collect 1×10 6 After lentiviral transfection, CD19-PD-1 / Nb CAR-T cells, CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells (Utd as negative control) were incubated with PE-anti His tag antibody in the dark, washed three times with PBS, and the expression of HIS-TAG and GFP fluorescent protein on the surface of CAR-T in each group was detected simultaneously by flow cytometry. The results showed that chimeric antigen receptors were expressed in T cells, such as Figure 6 shown.

[0063] (3) ELISA detection of CAR secretion of PD-1 single domain antibody targeting CD19

[0064] The PD-1 single domain antibody secreted by CD19-PD-1 / Nb CAR-T is labeled with HIS-TAG. The ELISA method was used to detect the content of HIS-TAG in the culture supernatant of each group of CAR-T cells to determine the secretion of PD-1 single domain antibody. 1×10 6 CD19-PD-1 / Nb CAR-T cells transfected with lentivirus and CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells Utd as negative control, the specific operation steps are as follows:

[0065] a. Prepare standard samples as required, with a maximum concentration of 200 pg / mL.

[0066] b. Soaking the ELISA plate: Take out the strips to be used, add 300 μL of washing solution to each well and let it soak for 30 seconds, then pat dry on absorbent paper.

[0067] c. Sample addition: Add 200 μL of standard to the standard wells, add 100 μL of cell culture medium to the blank wells, and add 100 μL of the supernatant of the cells to be tested to each sample well.

[0068] d. Add detection antibody: Add 50 μL of diluted antibody to each well, and try to ensure that the sample and detection antibody are added within 15 minutes.

[0069] e. Incubation: Seal the plate with a sealing film and incubate at room temperature with shaking at 300 rpm for 2 h.

[0070] f. Washing: discard the liquid in the well, add 300μL 1× washing solution, let stand for 1min, discard the liquid in the well. Then pat dry thoroughly on absorbent paper. Wash 6 times.

[0071] g. Add horseradish peroxidase: Add 100 μL of horseradish peroxidase-labeled streptavidin working solution to each well.

[0072] h. Incubation: Seal the plate with a new sealing film and incubate at room temperature with shaking at 300 rpm for 45 min.

[0073] i. Add substrate for color development: Add 100 μL of color development substrate TMB working solution to each well and incubate in the dark for 30 minutes.

[0074] j. Add stop solution: Add 100 μL of stop solution to each well. The liquid in the well will turn from blue to yellow. Mix thoroughly.

[0075] k. Result detection: Within 30 minutes, use an ELISA reader to perform dual wavelength detection, measure the maximum absorption wavelength of 450nm and analyze the data. The results are as follows Figure 7 shown.

[0076] Example 6 Cytotoxicity Analysis of CD19-PD-1 / Nb CAR-T Cells on Human Tumor Cells

[0077] PKH26 was used to stain target cells Raji, K562-CD19 and K562 ( Figure 8 The expression of CD19 on the surface of three types of cells, Raji, K562-CD19 and K562, was displayed. The CD19-PD-1 / Nb CAR-T cells prepared in Example 5 and the T cells cultured in Example 1 were taken respectively, and the corresponding number of effector T lymphocytes and target cells were added to a 24-well plate at an effector-target ratio (E:T) of 1:1, 5:1, and 10:1, respectively. After culturing for 16 hours, the above cells were collected, PI dye solution was added, and incubated at 4°C in the dark for 30 minutes. Centrifuge at 1200rpm for 6 minutes in a high-speed centrifuge, remove the supernatant, add 500μl of PBS to resuspend the cells, PKH26+PI+ are dead cells, and the proportion of PKH26+PI+ cells is detected by flow cytometry. The killing efficiency of CAR-T cells on different cells is calculated according to the formula. Among them, the killing rate = 100% × (apoptosis rate of experimental wells - apoptosis rate of natural release wells) / (100 - apoptosis rate of natural release wells), and the natural release wells are target cells without effector cells. As Fig. 9 As shown, CD19-PD-1 / Nb CAR-T cells have specific killing activity against tumor cells with high expression of CD19.

[0078] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A CAR-T cell that secretes a PD-1 single domain antibody targeting CD19, characterized in that: The CAR-T cell is a T cell modified by the chimeric antigen receptor CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the nucleotide sequence of the chimeric antigen receptor CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP comprises the nucleotide sequence shown in SEQ ID NO.

1.

2. The CAR-T cell according to claim 1, wherein the nucleotide sequence of the chimeric antigen receptor CD19Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP is the nucleotide sequence shown in SEQ ID NO.

1.

3. A method for preparing CAR-T cells according to claim 1, characterized in that: The method comprises the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of CD19 / Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb-IRES-GFP by PCR, recombining a lentiviral vector after enzyme digestion with the CAR target sequence obtained by PCR, transforming the recombinant lentiviral vector into Escherichia coli, screening positive clones, sequencing the positive clones to verify whether a lentiviral vector containing a CD19-PD-1 / Nb CAR sequence is successfully constructed, extracting plasmids from the recombinant positive clone strains that have been successfully sequenced, transfecting them into cells to be transfected, and then identifying the expression of the CD19-PD-1 / Nb CAR sequence in the cells by RT-PCR, verifying that the recombinant lentiviral vector can be expressed normally and then packaging the lentivirus, preparing T cells, and constructing the CAR-T cells by using lentiviral infection technology.

4. A method for preparing CAR-T cells according to claim 3, characterized in that: The method comprises the following steps: (1) Construction of a recombinant lentiviral vector containing the CAR target sequence: The CAR target sequence fragment of CD19 / Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb-IRES-GFP was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV400 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the primers on the target gene were used to perform PCR identification on the colonies screened with ampicillin antibiotics. The successfully identified bacterial liquid was sequenced. After successful sequencing, the plasmid was extracted using the Plasmid Mini Kit to obtain a plasmid containing the CAR target sequence; (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two helper plasmids Helper1.0 and Helper2.

0. After 48 hours, the green fluorescent protein expression of the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of green fluorescent protein-positive cells was counted. The virus titer was calculated according to the following formula: virus concentration = number of fluorescent cells / volume of virus stock solution; (3) T cell preparation: Isolate mononuclear cells from peripheral blood and culture them to obtain T cells; (4) Preparation of CD19-PD-1 / Nb CAR-T cells: T cells were cultured in a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine for 24 hours. The next day, the lentivirus solution was added to the T cells at an MOI of 20 and cultured in a 37°C CO2 incubator for 48 hours. The CAR-T cells were placed under a conventional microscope to observe the expression of green fluorescent protein in the CAR-T cells.

5. The preparation method according to claim 4, wherein in step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and a complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.

6. Use of the CAR-T cells secreting PD-1 single domain antibody targeting CD19 as claimed in claim 1 or 2 in the preparation of a preparation for treating tumors.

7. The use as claimed in claim 6, wherein the tumor is a CD19 positive tumor.

8. A pharmaceutical composition comprising the CAR-T cell according to claim 1 or 2 and a pharmaceutically acceptable carrier.

9. A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is CD19Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the nucleotide sequence is SEQ ID NO.

1.

10. A chimeric antigen receptor, wherein the chimeric antigen receptor is CD19 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb-GFP, and the chimeric antigen receptor is encoded by the nucleotide sequence shown in SEQ ID NO.1.

Citation Information

Cited By

  • In-vitro T cell depletion function evaluation method and application thereof in immunotherapy curative effect prediction

    CN122171424A